Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy.

Pharmacological research - 1 Feb 2026

Ye Yan, Zeng Qian, Ou Zuli, Ju Xiaoqian, Liao Qingyu, Li Canling, Zhang Dian, Wei Yu, Zhang Xiang, Wu Kejia, Chen Tingmei

Abstract excerpt

Bevacizumab is an anti-angiogenic agent widely used in neoadjuvant chemotherapy for advanced triple-negative breast cancer (TNBC). TNBC patients frequently acquire resistance to bevacizumab due to the hypoxic tumor microenvironment, yet the underlying molecular mechanism remains unclear. Here, we demonstrate that mitochondrial reprogramming under hypoxia is crucial for resistance to bevacizumab. Mechanically,...

Topics

Join the communities discussing this publication.

Angiogenesis Inhibitors
Bevacizumab
Drug Resistance, Neoplasm
Mice, Nude
Mitophagy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Pyruvate Dehydrogenase Acetyl-Transferring Kinase

Triple Negative Breast Neoplasms

Source

Identifiers

PMID: 41482011
DOI: 10.1016/j.phrs.2025.108081

Genes

PDK1
PHB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial pyruvate dehydrogenase kinase 1 drives bevacizumab resistance and malignant phenotype of TNBC by enhancing mitophagy.PMID 41482011Read ↗

Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.Semantic proximity Read ↗

Hypoxic mitochondria: accomplices in resistance.Semantic proximity Read ↗

Targeting DRP1 mediated mitochondrial metabolism as a novel treatment strategy for triple negative breast cancer (TNBC)Semantic proximity Read ↗

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read ↗

DRP1-mediated mitochondrial fission integrates growth hormone signaling with metabolic and stress adaptation in triple-negative breast cancerSemantic proximity Read ↗

Prohibitin2 knockdown decreases glioma malignant phenotypes and radio-resistance by inhibiting mitophagy.Semantic proximity Read ↗

Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogrammingSemantic proximity Read ↗

A Novel Therapeutic Target, BACH1, Regulates Cancer MetabolismSemantic proximity Read ↗

RBBP4 orchestrates glycolytic reprogramming and NF-κB-mediated immune evasion in triple-negative breast cancerSemantic proximity Read ↗

Expression of PGK1 in Breast Cancers Alters Their Sensitivity to Ferroptosis Induction via Metabolic ReprogrammingSemantic proximity Read ↗

PFKP is required for chemoresistant phenotype of breast cancer through modulating the formation of CD133+ cancer stem like cells.Semantic proximity Read ↗

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.